15880333

Source:http://linkedlifedata.com/resource/pubmed/id/15880333

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0018801, umls-concept:C0034380, umls-concept:C0087111, umls-concept:C0216784, umls-concept:C1274040, umls-concept:C1280500, umls-concept:C1524062
pubmed:issue	4
pubmed:dateCreated	2005-5-9
pubmed:abstractText	The effect on quality of life (QOL) of valsartan administered in addition to prescribed background heart failure therapy was assessed as a secondary endpoint in the Valsartan Heart Failure Trial (Val-HeFT).
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/15880333
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9442138
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor..., http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme..., http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Placebos, http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles, http://linkedlifedata.com/resource/pubmed/chemical/Valine, http://linkedlifedata.com/resource/pubmed/chemical/valsartan
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	1071-9164
pubmed:author	pubmed-author:CohnJay NJN, pubmed-author:GiardiniAnnaA, pubmed-author:GlazerRobertR, pubmed-author:HesterAllenA, pubmed-author:MajaniGiuseppinaG, pubmed-author:OpasichCristinaC, pubmed-author:TavazziLuigiL, pubmed-author:TognoniGianniG
pubmed:issnType	Print
pubmed:volume	11
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	253-9
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:15880333-Adrenergic beta-Antagonists, pubmed-meshheading:15880333-African Continental Ancestry Group, pubmed-meshheading:15880333-Aged, pubmed-meshheading:15880333-Angiotensin II Type 1 Receptor Blockers, pubmed-meshheading:15880333-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:15880333-Antihypertensive Agents, pubmed-meshheading:15880333-Drug Therapy, Combination, pubmed-meshheading:15880333-European Continental Ancestry Group, pubmed-meshheading:15880333-Female, pubmed-meshheading:15880333-Follow-Up Studies, pubmed-meshheading:15880333-Heart Failure, pubmed-meshheading:15880333-Humans, pubmed-meshheading:15880333-Male, pubmed-meshheading:15880333-Middle Aged, pubmed-meshheading:15880333-Placebos, pubmed-meshheading:15880333-Quality of Life, pubmed-meshheading:15880333-Sex Factors, pubmed-meshheading:15880333-Tetrazoles, pubmed-meshheading:15880333-Treatment Outcome, pubmed-meshheading:15880333-Valine
pubmed:year	2005
pubmed:articleTitle	Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
pubmed:affiliation	Salvatore Maugeri Foundation, Psychology Unit, Institute of Care and Scientific Research, Montescano, Pavia, Italy.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial